menu
    • menu
    [{"orgOrder":0,"company":"Redpin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"AAV-based Engineered Ion Channel Gene","moa":"Ion channel","graph1":"Neurology","graph2":"Preclinical","graph3":"Redpin Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Redpin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Redpin Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Redpin Therapeutics","sponsor":"Kriya Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Redpin Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Redpin Therapeutics \/ Kriya Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Redpin Therapeutics \/ Kriya Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Redpin Therapeutics

    Menu

    Redpin Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Redpin Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Redpin Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : Kriya Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Kriya Acquires Redpin Therapeutics, Adding Neurology Pipeline to Gene Therapy Portfolio

                            Details : The acquisition serves as the foundation for Kriya’s neurology therapeutic area portfolio, with two lead gene therapy programs focused on epilepsy and trigeminal neuralgia (TN).

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            November 16, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : Kriya Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Redpin Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Redpin Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AAV-based Engineered Ion Channel Gene

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Redpin Therapeutics Receives Four Additional US Patents

                            Details : Using our synthetic biology chemogenetics platform, Redpin has designed proprietary chimeric ligand-gated ion channels as targeted cell therapies to selectively stimulate or inhibit dysfunctional neuronal circuits implicated in a given disease.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            September 22, 2021

                            Lead Product(s) : AAV-based Engineered Ion Channel Gene

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth